Description
COMPOSITION: Each tablet contains Pazonpanib 400 mg
INDICATION: Pazopanib 400 mg is a potent muti-target tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFR) -1 ,-2, and -3, platelet- derived growth factor (PDGFR) -a, and -b, and stem cell factor receptor (c-KIT), with IC 50 values of 10, 30, 47, 71, 84 and 74 nM, respectively.
Pazokast is indicated for the treatment of patients with advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy. It is also indicated for the treatment of patients with advanced renel cell carcinoma.
PACKING: 30 Tablets / Bottle
